Hoping to land on its feet after a tough year and a long-time-coming buyout, Stada is nearly ready to announce seasoned drug industry executive Claudio Albrecht as its next CEO, according to one report. More: Stada close to naming pharma
read moreNovartis won its FDA approval for CAR-T drug Kymriah on Wednesday, but questions about pricing, access and more are just beginning. The company priced its groundbreaking therapy at $475,000, short of some market forecasts, but out of control for others
read moreLongtime Kite investors are set for big gains with Gilead Sciences’ $180-per-share buyout—and founder-CEO Arie Belldegrun will reap his fair share. He’ll receive about $598 million, in fact, for his 3.32 million shares—and a $15.5 million parachute on top of
read moreIn about eight months and with an outlay of more than $12 billion, the contract manufacturing industry has been transformed. Thermo Fisher Scientific has completed its $7.2 billion acquisition of CDMO Patheon, just weeks after Lonza completed its $5.5 billion
read moreDid Daiichi Sankyo turn away a buyout bid from AstraZeneca last year? According to the Japanese drugmaker, no. After Nikkei Business reported that news, Daiichi released a terse statement on Thursday saying, “this is not the fact.” It’s unclear whether
read moreThe prestigious PharmaTimes Marketer of the Year competition closes for entries and nominations at midnight tomorrow. If you haven’t entered yet, don’t panic! It takes less than a minute to fill out the online entry form – and you don’t
read more© 1994 - 2024 B.M. Pharmaceuticals